Feedzai Recognized as a Top Anti-Money Laundering Solution by Leading Analyst Firm

SAN MATEO, Calif., July 06, 2022 (GLOBE NEWSWIRE) — Feedzai, the world’s first RiskOps platform for financial risk management, has been ranked among the top vendors in anti-money laundering (AML) in a Forrester report released today, “The Forrester WaveTM: Anti-Money-Laundering Solutions, Q3 2022”.

“Feedzai leverages machine learning and automation to overcome the difficulty many institutions have with legacy AML programs which operate with siloed, disparate systems creating a pixelated view of risk,” said Pedro Barata, CPO at Feedzai. “We believe our continued investment in R&D alongside our unified RiskOps-based approach across AML is why we are consistently endorsed by customers and are a strong performer in the Forrester Wave report.”

In the last year, Feedzai’s AML suite has helped customers monitor over 200 territories with over 90% precision for high-priority alerts.

Findings in The Forrester WaveTM Anti-Money-Laundering Solutions report
Feedzai received the highest possible scores in the following criteria:

  • Internationalization, currencies and reporting
  • Execution roadmap
  • Enhancements: Watchlist management
  • Supporting services: Developers
  • Supporting services: Professional services

The Wave report cited “disproportionately strong development and support staffing” and also notes, “In its current AML offering, the vendor’s rule threshold, processing, and recommendation capabilities are strong.”

The analysis goes on to state, “Feedzai is a good fit for organizations looking to automate and streamline the AML model development using workflow templates and third-party risk scoring models.”

The Forrester Wave Anti-Money-Laundering Solutions, Q3 2022, reviewed 15 vendors in its assessment in a rigorous evaluation process that includes a detailed questionnaire, demos/briefings, and customer reference surveys/interviews. The resulting report is a trusted, unbiased analyst resource for organizations looking to invest in an AML solution.

Feedzai AML Suite manages AML risk across all stages of the customer lifecycle, creating a cohesive picture of risk across siloed internal and external systems. The suite includes four AML solutions in a single, unified AML compliance system:

  • Know Your Customer/Customer Due Diligence with continuous risk profiling,
  • Watchlist Management Customer Screening with automated watchlist monitoring,
  • Watchlist Management Payment Screening with fuzzy matching to reduce false positives, and
  • AML Transaction Monitoring that uses machine learning for precise risk scoring and prioritization.

About Feedzai:
Feedzai is the world’s first RiskOps platform for financial risk management, and the market leader in safeguarding global commerce with today’s most advanced cloud-based risk management platform, powered by machine learning and artificial intelligence. Feedzai is securing the transition to a cashless world while enabling digital trust in every transaction and payment type. The world’s largest banks, processors, and retailers trust Feedzai to protect trillions of dollars and manage risk while improving the customer experience for everyday users, without compromising privacy. Feedzai is a Series D company and has raised $282M to date with a current valuation of $1.5B. Its technology protects 900 million people in 190 countries. For more information, visit feedzai.com

For more information, please reach out to pr@feedzai.com

Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

FDA has set a target action date of December 23, 2022 for the toripalimab BLA –

– Toripalimab will be the first and only immuno-oncology agent for NPC in U.S., if approved –

SHANGHAI, China and REDWOOD CITY, Calif., July 06, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced today that the United States Food and Drug Administration (“FDA”) has accepted for review the Biologics License Application (“BLA”) resubmission for toripalimab in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma (“NPC”) and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy.

The FDA has set a Prescription Drug User Fee Act (“PDUFA”) action date for December 23, 2022. The Agency earlier communicated that the review timeline for the BLA resubmission would be six months, as onsite inspections in China would be required. Travel restrictions related to the COVID-19 pandemic previously hindered the FDA’s ability to complete required inspections. Coherus plans to launch toripalimab in the United States in the first quarter of 2023, if approved.

“Although the COVID-19 pandemic has created tremendous challenges for everyone, our dedication to bring better treatment options to patients around the world remains steadfast,” said Dr. Patricia Keegan, Chief Medical Officer of Junshi Biosciences. “Through our concerted efforts with our partner, Coherus, we have made continual progress towards obtaining toripalimab’s first marketing authorization outside of China. Over the next several months, we will work closely with the FDA to facilitate the review of this novel drug.”

“Toripalimab would address a critical unmet medical need for patients with nasopharyngeal carcinoma, an aggressive cancer for which there are currently no FDA-approved immunotherapy treatments. We collaborated closely with our partner, Junshi Biosciences, to complete the quality process changes requested by the FDA and facilitate the rapid resubmission of the toripalimab BLA,” said Dr. Theresa LaVallee, Chief Development Officer of Coherus.

“For Coherus, the toripalimab resubmission is one of several key development and commercialization milestones we are sharply focusing on over the next twelve months, and we are pleased with the Company’s execution and progress on all of them,” said Denny Lanfear, CEO of Coherus. “We now look forward to the August 2, 2022 target action date for our BLA for CIMERLI™, our Lucentis® biosimilar, followed by product launch which we are confident will be very successful. The toripalimab December 2022 PDUFA date follows directly, and the projected toripalimab launch in Q1 2023 will formally mark our entry into immuno-oncology, where Coherus will be one of just a handful of companies with a proprietary PD-1 as a foundation stone to build its oncology franchise upon. Lastly, twelve months from now, in July 2023, we expect to begin marketing our Humira® biosimilar, YUSIMRY®, which was approved by the FDA in December 2021. Preparations for that commercial launch are going very well. Biosimilar market execution is a demonstrated Coherus competency, and we believe that our commercialization strategy provides a robust framework against which we can successfully execute to meet our market expectations and share projections.”

Following approval of toripalimab for NPC, Coherus’ strategy in the US includes evaluating toripalimab’s ability to deliver substantial clinical benefit in significant indications, in combination with other cancer drugs and immunotherapies, through co-development agreements.

About Toripalimab in NPC
NPC is a type of aggressive cancer that starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull. Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with radiation and chemotherapy. In the United States, there are presently no immunotherapies approved for the treatment of NPC.

The toripalimab BLA is supported by the results from JUPITER-02, a randomized, double blind, placebo-controlled, international multi-center Phase 3 clinical trial, as well as POLARIS-02, a multi-center, open-label, pivotal Phase 2 clinical study. The JUPITER-02 results were first presented in June 2021 in a plenary session of the American Society of Clinical Oncology (“ASCO”) annual meeting (#LBA2) and subsequently published in detail as the cover article of the September 2021 issue of Nature Medicine. The POLARIS-02 results were published online in January 2021 in the Journal of Clinical Oncology.

The FDA has granted Breakthrough Therapy designation (“BTD”) for toripalimab in combination with chemotherapy (gemcitabine and cisplatin) for the 1st line treatment of recurrent, locally advanced or primary metastatic non-keratinizing NPC and for toripalimab monotherapy for patients with recurrent or metastatic non-keratinizing NPC with disease progression on or after platinum-containing chemotherapy. Additionally, the FDA has granted Orphan Drug designation for toripalimab for NPC.

In China, the National Medical Products Administration (“NMPA”) in 2021 approved toripalimab for two NPC indications.

About Toripalimab
Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells. In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are five approved indications for toripalimab in China.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers is the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In the face of the COVID-19 pandemic, Junshi Biosciences responded swiftly and strongly, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 2,800 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

About Coherus BioSciences
Coherus is a commercial stage biopharmaceutical company building a leading immuno-oncology franchise funded with cash generated by its FDA-approved products. In 2021, Coherus in-licensed toripalimab, an anti-PD-1 antibody, in the United States and Canada. The resubmission of the BLA for toripalimab for the treatment of NPC was accepted by the FDA in July 2022. Toripalimab is also being evaluated in pivotal clinical trials for the treatment of rare and highly prevalent cancers. Coherus markets UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta® in the United States, and expects to launch the FDA-approved Humira® biosimilar YUSIMRY™ (adalimumab-aqvh) in the United States in 2023. The FDA is currently reviewing the biologics license application for CIMERLI™, a biosimilar of Lucentis® (ranibizumab injection), with a target action date of August 2022.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Coherus’ ability to build its immuno-oncology franchise to achieve a leading market position; Coherus’ ability to generate cash; Coherus’ investment plans; Coherus’ expectations for the launch dates of toripalimab, CIMERL™ and YUSIMRY™; Coherus’ plans to file additional BLAs for toripalimab and pursue co-development agreements for other indications; beliefs about toripalimab’s ability to address an unmet need for patients; expectations about the success and timing of the FDA review of toripalimab and CIMERLI™; and Coherus’ ability to meet market expectations and share projections in the future.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; risks relating to the COVID-19 pandemic; risks related to our existing and potential collaboration partners; risks of the drug development position of Coherus’ competitors; the risks and uncertainties of the regulatory approval process, including the speed of regulatory review, international aspects of Coherus’ business, and the need to have the FDA finish inspections in China during a COVID-19 pandemic; the risk of FDA review issues; the risk of Coherus’ execution of its change in strategy from a focus on biosimilars to a strategy using cash from its portfolio to fund an immuno-oncology franchise; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ drug candidates; and the risks and uncertainties of possible litigation. All forward-looking statements contained in this press release speak only as of the date of this press release. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the significant risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022, filed with the Securities and Exchange Commission on May 5, 2022, including the section therein captioned “Risk Factors” and in other documents Coherus files with the Securities and Exchange Commission.

UDENYCA®, CIMERLI™ and YUSIMRY™, whether or not appearing in large print or with the trademark symbol, are trademarks of Coherus, its affiliates, related companies or its licensors or joint venture partners, unless otherwise noted. Trademarks and trade names of other companies appearing in this press release are, to the knowledge of Coherus, the property of their respective owners.

Junshi Biosciences Contact Information:
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Coherus Contact Information:
IR Contact:
McDavid Stilwell
Chief Financial Officer
Coherus BioSciences, Inc.
IR@coherus.com

Media Contact:
Kelli Perkins
Red House
kelli@redhousecomms.com

Dominica Proudly Hosts Cricket T20 International Matches at Windsor Park Sports Stadium

Roseau, July 06, 2022 (GLOBE NEWSWIRE) — The Commonwealth of Dominica has proudly hosted cricket T20 international matches at the Windsor Park Sports Stadium a five-year hiatus. The nation hosted two back-to-back games which were held on 2 and 3 July 2022.

The Windsor Park Sports Stadium, situated in the capital city Roseau, is one of the official venues for the T20I Bangladesh tour of the West Indies. Prior to these matches, the stadium witnessed four international matches; the first was a One Day International (ODI) played between West Indies and Bangladesh in the year 2009, and the second was also ODI, which was played between West Indies and South Africa in 2010.

Followed by the third match (first T20I), which was played by the West Indies and New Zealand in 2014, and the fourth was a Test Match between West Indies and Pakistan in the year 2017.

During the match, the authorities took special care of the audience’s entertainment and provided a “Carnival-like” atmosphere to the fans and patrons in the interim with the local Dominican cultural presentation.

The Director of Tourism of Dominica, Colin Piper praised the government for the successful hosting of the international matches. He outlined, “The Discover Dominica Authority would like to express its gratitude to the Government of the Commonwealth of Dominica and Cricket West Indies for their efforts and assistance in bringing international cricket back to the country after a five-year absence.”

He further expressed pleasure that the two T20I matches in Dominica on July 2nd and 3rd were fantastic and witnessed a strong turnout of local, regional, and international cricket fans to enjoy the fixtures.

Events Management Executive of Cricket West Indies, Joneé Charles, also lauded Dominica for welcoming international cricket with such enthusiasm. She stated, “We are delighted that Dominica was chosen as the host of two matches, and we also hope to host more in the future. After a challenging two years owing to the pandemic, we must express our gratitude to the local organizing committee and Cricket West Indies for staging these T20I matches.”

Dominica has been able to host international matches on its land because of the efforts of the government. The government has been continuously making efforts to uplift the sports infrastructure in the country.

Recently, the Sports Division of Dominica upgraded the Windsor Park Sports Stadium; the authorities contributed to the refurbishment of the lawn. Earlier, new electronic scoreboards were installed at the Windsor Stadium. Prior to the installation, a protective structure was constructed to ensure the safety of the scoreboard, ensuring a more resilient system. The cost of the scoreboard was near ECD 1 million. The previous board was destroyed during Hurricane Maria hit the country in 2017.

Dominica has been creating stronger sporting bodies such as clubs and sports committees and has also been formalizing the National Sports Council, which is in progress as the documents have been drafted. The government has also been working to put the task force in place and has assigned a coordinator.

The government of Dominica has been uplifting the sports infrastructure through the funds generated through the Citizenship by Investment (CBI) Programme of the country.

Citizenship by Investment of Dominica:

The programme is known to be one of the longest-running, safe and most secure in the world. Launched in 1993, Dominica has been providing alternative citizenship for around three decades.

The funds generated with the help of the programme largely contribute to the development and rehabilitation of resilient infrastructure, including schools, hospitals, healthcare centres, bridges and more. The government has been heavily investing in building the world’s first climate-resilient country which can withstand natural calamities such as Tropical Storms, Hurricanes as well as Cyclones.

Interested investors may apply for alternative citizenship of Dominica through two investment options – Economic Diversification Fund (EDF) and Real Estate Fund Option.

The Economic Diversification Fund (EDF) is a government-supported initiative which contributes toward socio-economic development and helps in the upliftment of the country. The fund generated with the EDF goes towards improving projects in the public and private sectors. To date, the funds generated have assisted in the development of schools, hospitals, sports stadiums and numerous sectors such as tourism and agriculture.

The minimum investment required to apply for the alternative citizenship of Dominica is USD 100,000.

To apply under the Real Estate Investment Option, the applicant has to apply for government-approved properties. The minimum investment required is USD 200,000.

About Dominica:
The magical island of the Caribbean, Dominica is a beautiful destination for anyone who wants to explore and discover exquisite volcanic landscapes, jungles, and tropical beaches.

Dominica is home to the world’s second-largest boiling lake and comprises of nine volcanoes that are entirely safe to visit.

Due to so many volcanoes on the small island country, many beaches in Dominica naturally have greyish-black sand. Mero Beach is one of the famous beaches of the Commonwealth of Dominica.

Besides the magnificent volcanoes and beaches, Dominica also has an extraordinary number of rivers. Some of these rivers are cool and clear blue, while others are fast and cloudy, but almost all rivers are surrounded by exotic flora. The Indian River on the island is the widest of all.

Dominica is popularly known as the ‘Nature Island of the Caribbean’. The island also has the largest settlement of indigenous people in the whole Caribbean region.  

PR Dominica
Commonwealth of Dominica
001 (767) 266 3919
cbiusecretary@dominica.gov.dm

Webtel.Mobi’s “Metaverse” Platform – With its Potentially Crypto-Replacing Global Digital Currency and CBDC Equivalents – Plans a Special Purpose Vehicle Listing in the US

Global Telco plans to list an SPV holding a percentage of its stock on a US Stock Exchange. Significant interest is being generated due to its “Metaverse” Payments Platform and its potentially Crypto & Stablecoin-replacing “TUVs” – its fully functional and 100%-secured Multicurrency Global Digital Currency and CBDC equivalents

WM Platform 2 Recommencing Unrestricted Global Operations

WM Platform 2 Recommencing Unrestricted Global Operations

LONDON and NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) — Global Telephony Provider Webtel.mobi (“WM”) is planning to list an SPV holding a percentage of its shares on a US Stock Exchange. Significant interest is being generated both because of the wide range of products and services provided globally by WM’s AI-controlled “Metaverse” Platform, and the potential volumes in this market sector.

Although WM does not refer to its Platform as being a “Metaverse” Platform, but rather as a “Whole Market” Platform, commentators have increasingly referred to it as a Metaverse. This is because its multiple Systems cover virtually the entire global market of payment and transfer transactions, across all industries and sectors, in all countries and markets worldwide. It is also due to its provision of 100%-secured Multicurrency Digital Currency and CBDC equivalents (called “TUVs”), and its AI-controlled “VSMP” business model – whereby any persons or entities worldwide can acquire a Virtual WM Platform for their own application.

Multitrillion Dollar Metaverse Market Predictions

https://tinyurl.com/MS-Articlehttps://tinyurl.com/GS-Articlehttps://tinyurl.com/HSBC-JPM-Articlehttps://tinyurl.com/CIti-Article https://tinyurl.com/KPMG-Article

Some experts regard WM’s Global Multicurrency Digital Currency and CBDC equivalents as a potential replacement for Cryptocurrencies and Stablecoins, while others view its TITAN Global Account Number and ICLM Transfer System as a proven alternative to the global SWIFT System. Those products, combined with the company’s close-to-zero running costs and its multi-spectrum Global Telecommunications System and Global Online & Offline Payments Systems across all sectors and industries – in what the world’s largest banks and financial services companies are describing as the world’s largest market – are what is generating the significant interest in WM and its planned SPV listing.

According to some of the biggest names in Finance and business internationally, the “Metaverse” Market is the largest market that has existed to date. Firms such as Morgan Stanley, Goldman Sachs, JP Morgan, HSBC and Citi have stated it is a USD 8 Trillion to USD 13 Trillion market, while other major firms such as KPMG have stated that estimates of the market’s size are conservative.

Among the suite of WM’s “Metaverse” (or “Whole Market”) products, services and utilities in this Multitrillion Dollar Market are the following:

  • WM’s Global AI-Controlled Telecommunications Platform
    The “Specialized Mobile and Landline System”: For ultra-low cost Mobile and Landline calls and Mobile Texts to, from, and in all countries worldwide from all Mobile and Fixed-Line Telephones. The Telecommunications Infrastructure and Platform is the Platform through which all its other Converged Services are delivered.
  • WM’s Global AI-Controlled Digital Currency equivalent – also a Global Wholesale and Retail CBDC equivalent
    The “TUV System”: The Company provides three types of TUV:

    • The Standard TUV: A Global, Multicurrency Digital Currency equivalent and CBDC equivalent. It is instantly transferrable for transfers and payments, convertible between currencies, and redeemable to bank accounts or kiosks – secured for 100% of the face value currency in funds to that amount.
    • The Secured TUV: This has all the characteristics of the Standard TUV, but is additionally secured for 100% of the face value currency in physical gold to that amount. This aspect – together with its capacity for its conversion between currencies – further protects against currency depreciation / currency crashes and inflation.
    • The Smart TUV: A fully Owner-Programmable version of a Standard or Secured TUV – which renders most existing forms of transaction contracts and intermediaries redundant as the Programmable Currency itself regulates Performance and Payments during, and for all transaction types, durations and circumstances.
  • WM’s Global AI-Controlled Multicurrency Account and Account Number System
    The “TITAN System” and “ITAN Account Numbers”: A global unitary and centrally-controlled Account Number and Accounts system, with free multicurrency account wallets for receipt and storage of multicurrency loads, transfers and payments, using stored credit within the WM Members-Only Closed Loop System and ecosystem.
  • WM’s Global AI-Controlled Online and Offline Payments Systems
    The “ICLM Payments System”: A global unitary and centrally-controlled Online and Offline Multicurrency Payments System that enables instant Multicurrency Payments and Payment-receipt – including instant Remitter-controlled FX Conversions and instant System-controlled processing and settlement – worldwide, 24/7/365, within the WM Members-Only Closed Loop System and ecosystem.
  • WM’s Global AI-Controlled Transfer System
    The “ICLM Transfers System”: A global unitary and centrally-controlled Multicurrency Transfer System that enables instant Multicurrency Transfers and Transfer-receipt – including instant Transferor-controlled FX Conversions and instant System-controlled processing and settlement – worldwide, 24/7/365, within the WM Members-Only Closed Loop System and ecosystem.
  • WM’s Global AI-Controlled Currency Swap System
    The “Currency Swap”: A global Pure Peer to Peer (“PP2P”) Multicurrency Currency Swap system. It enables Members to carry out instant Currency Swaps directly between each other, at exchange rates negotiated between themselves, outside of the Global FX Market and its bank-set rates.
  • WM’s Global AI-Controlled Zero-Cost Marketing, Support and Fulfilment Models
    The “VSMP” or “Virtual Specialized Mobile Provider System”. This System brings about a close-to-zero-cost Global Operating Model through the utilization of AI-controlled 21st Century technological and communication capacities, via which all and any Member-based, Commercial or other organizations worldwide obtain their own version of the WM System and Platforms free, and utilize it for their own revenue-generation.
  • WM’s Global AI-Controlled Zero-Cost KYC and AML Model
    This System is the most advanced and safe global KYC and AML system currently operational internationally, whereby full KYC and AML processes are applied and reverified by qualified Attorneys and/or Notaries worldwide on all WM or WM-Affiliate (VSMP) Members prior to their being able to utilize many of WM’s Members-Only Closed Loop Platforms and Facilities.
  • WM’s Global AI-Controlled Clearing System
    The AI-controlled WM System in its Converged Totality. This realizes and has brought into being a fully-functional version of John Maynard Keynes’ “International Clearing Union” (wherein the TUV realizes and brings into being Keynes’ envisaged “Bancor” instrument).
  • The solution for the Unbanked Market and a benign Cash-Replacement
    The WM System in its totality also provides the first fully-functional and fully-operational global product that brings the Unbanked and/or Underbanked markets fully into the 21st Century Digital Economy, and simultaneously provides a workable and working system that replaces cash without infringing on peoples’ privacy or rights.

The WM services are difficult for incumbents to compete against, because they function at faster speeds and higher levels of security than any other similar services, are Pure-Peer-to-Peer (“PP2P”) without intermediaries, and – most importantly – are provided either free of charge or at ultra-low costs.

WM is able to provide its Converged services – including in-house instant processing, settlement, Real Time Gross Settlement and Payment versus Payment services – at zero cost or ultra-low costs because they all function via / off its Telephony Systems, Services and Platforms. As such, they function at zero additional cost to WM.

All of WM’s Systems, Platforms, Facilities, Products and Services were fully tested, due diligenced and proven in over eight years of fully-operational Restricted Global Operations to a restricted number of Members with its Platform 1. The results of that testing were then fed into the rebuild of WM’s Refined Platform 2.

WM’s Platform 2 is now fully completed, tested and ready to recommence Unrestricted Global Operations, and already has Global Affiliates with over 288 Million Members within them.

WM is listing the SPV on a US Retail Stock Exchange to open use of its Secured and Smart TUVs to a wider group of people. This is because for an initial period, although the Standard TUV will be available to all WM Members, the Secured TUV and Smart TUV will only be available for acquisition and use by members who are WM Shareholders and Shareholders of the SPV to be listed in the US. WM’s shares are not available to the public, so the SPV listing is a way to enable wider spread of accessibility to these specialized TUVs. This will also give some of WM’s early investors an opportunity to acquire some liquidity for their WM shares – which will form the asset of the SPV.

The Company is listing the SPV prior to its Recommencement of Unrestricted Global Operations. This is because its experience from its eight years of previous Global Operations with Platform 1 showed that even with full AI-control of the System, Global Operations (all countries and territories) as opposed to International or Multinational Operations (some countries or many countries) is so vast on a 24/7/365 basis, that it will leave no time for the listing once it is recommenced.

WM itself is not listing because it does not require funding to progress its Global Operations and expansion. Its build, development, operational and other costs were covered by its founders and a small group of private shareholders, and it has no debts and no institutional funding or institutional shareholders. This is also why although WM was previously granted Eligibility by the United Kingdom Listing Authority and the Primary Markets Team of the London Stock Exchange to carry out a Standard Listing on the Main Board of the London Stock Exchange, it declined to do so.

More information on WM is available in a redacted for public version of its most recent internal report to its private shareholders, which is attached to this article.

Resources:

WM Media Contact:
Nick Lambert: wm@thoburns.com

Research Papers on the WM System’s Converged Capacities by Professor Jan Kregel of the Levy Economics Institute:

Media Articles on WM:
https://webtel.mobi/info/current-media/

Attachment:
Webtel.mobi (Holdings) Limited – Redacted Report – June 2022

WM’s urls:
https://webtel.mobi/pc (Tablets / Laptops / Desktops)
https://webtel.mobi (Smart Phones)
https://webtel.mobi/wap (Pre-Smart Mobile Phones)

Photos accompanying this announcement are available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/21684770-2700-4933-acd3-5ee9b115f8b6
https://www.globenewswire.com/NewsRoom/AttachmentNg/04a25cac-52e9-47f0-a58f-934af21546b9

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

Long-term Infant Data Provides Reassurance on Novel Capacitation – In vitro Maturation (CAPA-IVM) Fertility Method

WILMINGTON, Del., July 06, 2022 (GLOBE NEWSWIRE) — A new 2-year infant follow-up study reported no difference in developmental outcomes in children born after capacitation-in vitro maturation (CAPA-IVM) compared to those born through conventional in vitro fertilization (IVF) following ovarian stimulation. The study was designed to detect developmental delay in children in terms of communication, gross motor, fine motor, problem solving and personal-social behavior. It included a total of 231 children who were evaluated at 6 months, 12 months and 24 months after birth.

The study results were presented by Prof. Dr. Tuong M Ho at the 38th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) on July 6th, 2022 in Milano (Italy) and have been published in Human Reproduction1, a leading reproductive medicine journal.

Prof. Dr. Lan Vuong from MyDuc hospital, HCMC, Vietnam, who led the study, said: “One of the key messages of this study is that there does not appear to be any significant concern about the safety of CAPA-IVM on childhood development.” The current results complement recent findings that CAPA-IVM does not show any major epigenetic alterations or imprinting defects in in-vitro matured oocytes2. Dr. Vuong believes that continuing building evidence on CAPA-IVM is important to physicians considering alternative approaches to current fertility treatment.

About CAPA-IVM

CAPA-IVM is a novel approach to in-vitro maturation of oocytes recovered after no or minimal ovarian stimulation, that incorporates a capacitation step in the maturation of oocytes in vitro which enhances oocyte developmental competence. CAPA-IVM is a patient-friendly assisted reproductive technology method that may become an alternative option to conventional ovarian stimulation and IVF, with reduced treatment burden for the patient. The worldwide rights to the CAPA-IVM technology are owned by Lavima Fertilty, Inc.

References

1. Vuong LN, Nguyen MHN, Nguyen NA, Ly TT, Tran VTT, Nguyen NT, Hoang HLT, Le XTH, Pham TD, Smitz JEJ, Mol BW, Norman RJ, Ho TM. Development of children born from IVM versus IVF: 2-year follow-up of a randomized controlled trial. Human Reproduction 2022, pp. 1–9, deac115,

2. Saenz-de-Juano MD, Ivanova E, Romero S, Lolicato F, Sánchez F, Van Ranst H, Krueger F, Segonds-Pichon A, De Vos M, Andrews S, Smitz J, Kelsey G, Anckaert E. DNA methylation and mRNA expression of imprinted genes in blastocysts derived from an improved in vitro maturation method for oocytes from small antral follicles in polycystic ovary syndrome patients. Human Reproduction 2019 Sep 29;34(9):1640-1649.

Contact

andre.rosenthal@lavimafertility.com

Fluence Announces India Technology Centre, Underscoring Commitment to the Region and Execution of Global Product Strategy

Fluence India Technology Centre, located in Bangalore, will serve as an engineering centre of excellence for supporting customers globally and in India

Fluence India Technology Centre

The Fluence India Technology Centre supports the company’s global product strategy by growing engineering capabilities and scaling global talent, and strengthens Fluence’s local presence in India.

BANGALORE, India, July 06, 2022 (GLOBE NEWSWIRE) — Fluence Energy, Inc. (“Fluence”) (Nasdaq: FLNC), a global market leader in energy storage products, services, and digital applications for renewables and storage, today announced the opening of a new global technology centre in Bangalore. The Fluence India Technology Centre supports the execution of the company’s global product strategy by growing engineering capabilities and scaling global talent and strengthens Fluence’s local presence in the country.

The Fluence India Technology Centre marks a significant milestone for Fluence, becoming the company’s first technology centre based entirely in Asia. This complements existing technology teams in North America and Europe. Together, the company’s technology centre teams support Fluence’s regionally focused operational model and create a strong foundation for new product introductions and regionalized product support.

With the launch of this technology centre, we will enhance our product offerings, engineering capabilities, and further demonstrate our core competencies in battery-based energy storage products and software,” said Fluence SVP & Chief Product Officer Rebecca Boll. “This team will be key to the expansion of our sixth generation product line, which is delivering a range of critical grid services to customers around the world, as well as the creation of next generation products.”

Fluence’s team of technical experts in Bangalore will support the company’s global sales and growth objectives for all major product lines and enable flexibility and speed in product development. As the company’s largest global technology team, employees at the India Technology Centre are working in the areas of enclosure, battery, and inverter engineering, software quality assurance, product management, and more. Additionally, the technology centre will support the delivery of products to the Fluence India joint venture with ReNew Power and support the full lifecycle of their storage systems.

“India has an ambitious renewable energy capacity target of 500 GW by 2030. Fluence is committed to supporting India in the clean energy transition and our technology centre and joint venture with ReNew are just the beginning,” said Fluence SVP & President, APAC Jan Teichmann. “Our investment in the region will enable us to partner with customers locally, develop expertise in local market requirements, drive product development for the region, and support the long-term growth of energy storage in India.”

Fluence’s flagship battery-based energy storage project in India was deployed in 2019 at a Tata Power (TPDDL) substation in Delhi. The 10 MW / 10 MWh project was developed by AES and Mitsubishi and is the largest energy storage system in South Asia.

About Fluence:

Fluence Energy, Inc. (Nasdaq: FLNC) is a global market leader in energy storage products and services, and digital applications for renewables and storage. With a presence in 30 global markets, Fluence provides an ecosystem of offerings to drive the clean energy transition, including modular, scalable energy storage products, comprehensive service offerings, and the Fluence IQ Platform, which delivers AI-enabled digital applications for managing and optimizing renewables and storage from any provider. The company is transforming the way we power our world by helping customers create more resilient and sustainable electric grids. For more information, visit our website or follow us on LinkedIn or Twitter.

Forward-Looking Statement

The information in this press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release are forward-looking statements, including, without limitation, the anticipated engineering services that Fluence Technology Centre India may provide to Fluence customers in India and the globe.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments, as well as a number of assumptions concerning future events, and their potential effects on our business. These forward-looking statements are not guarantees of performance, and there can be no assurance that future developments affecting our business will be those that we have anticipated. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside Fluence’s control and are difficult to predict. Factors that may cause such differences in expected results include but are not limited to the following: actual use of the technology centre services by customers in practice, the ability to adequately answer Fluence customers questions and assist them in the maintenance and operation of their energy storage systems in real time, and the technology centre’s ability to run and operate without any defects or errors. Fluence cautions that the foregoing list of factors is not exclusive. Additional information about factors that could materially affect Fluence is set forth under the “Risk Factors” section in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, and available on the SEC’s website at www.sec.gov.

Except as otherwise required by applicable law, Fluence disclaims any duty to update any forward-looking statements contained in this press release, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. Should underlying assumptions prove incorrect, actual results and projections could differentiate materially from those expressed in any forward-looking statements.

Media Contact

Adele Zhang
Head of Marketing & Communications, APAC
+61 406529688
Adele.Zhang@fluenceenergy.com

Investor Relations Contact

Lexington May
Sr. Manager, Investor Relations
+1 713-909-5629
InvestorRelations@fluenceenergy.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9c937377-d953-4d07-aa27-7ccb82018645